The spread of carbapenem-resistant Enterobacteriaceae in South Africa: Risk factors for acquisition and prevention

South African Medical Journal

Volumn 102, Issue 7, 2012, Pages 599-601

  Brink, Adrian ^a   Coetzee, Jennifer ^b   Clay, Cornelis ^b   Corcoran, Craig ^b   van Greune, Johan ^c   Deetlefs, J D ^c   Nutt, Louise ^d   Feldman, Charles ^e   Richards, Guy ^e   Nordmann, Patrice ^f   Poirel, Laurent ^f  

^a MILPARK HOSPITAL   (South Africa)

^b National Reference Laboratory   (South Africa)

^c Ampath National Laboratory Services   (South Africa)

^d Ampath National Laboratory Services   (South Africa)

^e UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^f BICÊTRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; CARBAPENEM; CARBAPENEMASE; METALLO BETA LACTAMASE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL INFECTION; CARBAPENEM RESISTANT ENTEROBACTERIACEAE; DISEASE TRANSMISSION; DRUG EXPOSURE; DRUG USE; ENTEROBACTER CLOACAE; ENTEROBACTERIACEAE; HEALTH CARE; HUMAN; INFECTION CONTROL; INVASIVE PROCEDURE; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; PREVALENCE; RISK FACTOR; SERRATIA MARCESCENS; SOUTH AFRICA; URINARY CATHETER;

EID: 84863749825     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: 10.7196/samj.5789     Document Type: Article

References (15)

1. Brink AJ, Feldman C, Richards GA, et al. Emergence of extensive drug resistance (XDR) among Gram-negative bacilli in South Africa looms nearer. S Afr Med J 2008;98:586-592.
2. Nordmann P, Naas T, Poirel L. Global spread of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 2011;17:1791-1798. [http://doi.org/10.3201/eid1710.110655]
3. Gupta N, Lumbago BM, Patel JB, et al. Carbapenem-resistant Enterobacteriaceae: Epidemiology and prevention. Clin Infect Dis 2011;53:60-67. [http://doi.org/10.1093/cid/cir202]
4. Brink AJ, Coetzee J, Clay C, et al. Emergence of New Delhi metallo-beta-lactamase (NDM-1) and Klebsiella pneumoniae carbapenemase (KPC-2) in South Africa. J Clin Microbiol 2012;50:525-527. [http://doi.org/10.1128/JCM.05956-11]
5. Kontopoulou K, Protonotariou E, Vasilakos K, et al. Hospital outbreak caused by Klebsiella pneumoniae producing KPC-2 β-lactamase resistant to colistin. J Hosp Infect 2010;76:70-73. [http://doi.org/10.1016/j.jhin.2010.03.021]
6. Zarkotou O, Pournaras S, Voulgari E, et al. Risk factors and outcomes associated with acquisition of colistin-resistant KPC-producing Klebsiella pneumoniae: a matched case-control study. J Clin Microbiol 2010;48:2271-2274. [http://doi.org/10.1128/JCM.02301-09]
7. Brink AJ, Botha RF, Poswa X, et al. Antimicrobial susceptibility of Gram-negative pathogens isolated from patients with complicated intra-abdominal infections in South African hospitals (SMART Study 2004-2009): Impact of the new carbapenem breakpoints. Surg Infect 2012;13:1-7. [http://doi.org/10.1089/sur.2011.074]
8. Bamford C, Bonorchis K, Ryan A, et al. Antimicrobial susceptibility patterns of selected bacteraemic isolates from South African public sector hospitals, 2010. Southern African Journal of Epidemiology and Infection 2011;26:243-250.
9. Kritsotakis EI, Tsioutis C, Roumbelaki M, et al. Antibiotic use and the risk of carbapenem-resistant extended-spectrum-β-lactamase-producing Klebsiella pneumoniae infection in hospitalized patients: results of a double case-control study. J Antimicrob Chemother 2011;66:1383-1391. [http://doi.org/10.1093/jac/dkr116]
10. Won SY, Munoz-Price LS, Lolans K, et al. Emergence and rapid regional spread of Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae. Clin Infect Dis 2011;53:532-540. [http://doi.org/10.1093/cid/cir482]
11. Patel N, Harrington S, Dihmess A, et al. Clinical epidemiology of carbapenem-intermediate or-resistant Enterobacteriaceae. J Antimicrob Chemother 2011;66:1600-1608. [http://doi.org/10.1093/jac/dkr156]
12. Hirsch EB, Tam VH. Detection and treatment options for Klebsiella pneumonia carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. J Antimicrob Chemother 2010;65:1119-1125. [http://doi.org/10.1093/jac/dkq108]
13. Roberts JA, Kruger P, Paterson DL, et al. Antibiotic resistance-what's dosing got to do with it? Crit Care Med 2008;36:2433-2440.
14. Imberti R, Cusato M, Villani P, et al. Steady state pharmacokinetics and BAL concentration of colistin in critically ill patients after IV colistin methanesulfonate administration. Chest 2010;138:1333-1339.
15. Best Care... Always! www.bestcare.org.za (accessed 17 February 2012).